keyword
MENU ▼
Read by QxMD icon Read
search

Fallopian tube cancer

keyword
https://www.readbyqxmd.com/read/28109627/a-final-report-of-a-phase-i-study-of-veliparib-abt-888-in-combination-with-low-dose-fractionated-whole-abdominal-radiation-therapy-ldfwar-in-patients-with-advanced-solid-malignancies-and-peritoneal-carcinomatosis-with-a-dose-escalation-in-ovarian-and-fallopian
#1
Kim A Reiss, Joseph M Herman, Deborah Armstrong, Marianna Zahurak, Anthony Fyles, Anthony Brade, Michael Milosevic, Laura A Dawson, Angela Scardina, Patricia Fischer, Amy Hacker-Prietz, Robert J Kinders, Lihua Wang, Alice Chen, Sarah Temkin, Naomi Horiba, Lee-Anne Stayner, Lillian L Siu, Nilofer S Azad
BACKGROUND: The combination of low-dose radiation therapy with PARP inhibition enhances anti-tumor efficacy through potentiating DNA damage. We combined low-dose fractionated whole abdominal radiation (LDFWAR) with ABT-888 in patients with peritoneal carcinomatosis with a dose escalation in ovarian and fallopian cancer patients (OV). METHODS: Patients were treated with veliparib, 40-400mg orally BID on days 1-21 of 3 28-day cycles on 6 dose levels. Dose levels 5 and 6 included only OV patients...
January 18, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28106106/serous-tubal-intraepithelial-neoplasia-the-concept-and-its-application
#2
REVIEW
Emily E K Meserve, Jan Brouwer, Christopher P Crum
In recent years it has become clear that many extra-uterine (pelvic) high-grade serous carcinomas (serous carcinomas) are preceded by a precursor lesion in the distal fallopian tube. Precursors range from small self-limited 'p53 signatures' to expansile serous tubal intraepithelial neoplasms that include both serous tubal epithelial proliferations (or lesions) of uncertain significance and serous tubal intraepithelial carcinomas. These precursors can be considered from three perspectives. The first is biologic underpinnings, which are multifactorial, and include the intersection of DNA damage with Tp53 mutations and disturbances in transcriptional regulation that increase with age...
January 20, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28101406/design-and-characterization-of-a-combined-oct-and-wide-field-imaging-falloposcope-for-ovarian-cancer-detection
#3
Molly Keenan, Tyler H Tate, Khanh Kieu, John F Black, Urs Utzinger, Jennifer K Barton
Early detection of ovarian cancer is only achieved in around 20% of women due to lack of effective screening. We propose a method for surveillance of high risk women based on a microendoscope introduced transvaginally to image the fallopian tubes and ovaries. This requires extreme miniaturization of the optics and catheter sheath. We describe the design of a falloposcope that combines optical coherence tomography (OCT) and wide field imaging into a sub-1 mm diameter package. We characterize the systems and show that they provide contrast on ex-vivo samples of ovary and fallopian tube...
January 1, 2017: Biomedical Optics Express
https://www.readbyqxmd.com/read/28089377/phase-ii-trial-of-albumin-bound-paclitaxel-and-granulocyte-macrophage-colony-stimulating-factor-as-an-immune-modulator-in-recurrent-platinum-resistant-ovarian-cancer
#4
John B Liao, Ron E Swensen, Kelsie J Ovenell, Katie M Hitchcock-Bernhardt, Jessica L Reichow, Minjun C Apodaca, Leonard D'Amico, Jennifer S Childs, Doreen M Higgins, Barbara J Buening, Barbara A Goff, Mary L Disis
BACKGROUND: Granulocyte macrophage colony-stimulating factor (GM-CSF) stimulates immunity via recruitment of antigen presenting cells and tumor specific T-cell stimulation. Albumin-bound paclitaxel (nab-paclitaxel) followed by GM-CSF may enhance antitumor responses and prolong remissions in ovarian cancer. Immune phenotypes present before treatment may identify responders to chemo-immunotherapy. METHODS: Recurrent platinum-resistant ovarian, peritoneal, or fallopian tube cancer patients received nab-paclitaxel, 100mg/m(2) days 1, 8, 15 followed by GM-CSF 250μg days 16-26 every 28days for 6 planned cycles...
January 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28089376/chemotherapy-completion-in-elderly-women-with-ovarian-primary-peritoneal-or-fallopian-tube-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#5
Vivian E von Gruenigen, Helen Q Huang, Jan H Beumer, Heather A Lankes, William Tew, Thomas Herzog, Arti Hurria, Robert S Mannel, Tina Rizack, Lisa M Landrum, Peter G Rose, Ritu Salani, William H Bradley, Thomas J Rutherford, Robert V Higgins, Angeles Alvarez Secord, Gini Fleming
PURPOSE: A simple measure to predict chemotherapy tolerance in elderly patients would be useful. We prospectively tested the association of baseline Instrumental Activities of Daily Living (IADL) score with ability to complete 4 cycles of first line chemotherapy without dose reductions or >7days delay in elderly ovarian cancer patients. PATIENTS AND METHODS: Patients' age ≥70 along with their physicians chose between two regimens: CP (Carboplatin AUC 5, Paclitaxel 135mg/m(2)) or C (Carboplatin AUC 5), both given every 3weeks either after primary surgery or as neoadjuvant chemotherapy (NACT) with IADL and quality of life assessments performed at baseline, pre-cycle 3, and post-cycle 4...
January 12, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28072594/genetics-consultation-rates-following-a-diagnosis-of-high-grade-serous-ovarian-carcinoma-in-the-canadian-province-of-ontario
#6
Jacob McGee, Karen Panabaker, Sean Leonard, Peter Ainsworth, Laurie Elit, Salimah Z Shariff
OBJECTIVE: In 2001, the province of Ontario expanded cancer genetic testing eligibility to include all women with high-grade serous ovarian carcinoma (HGSC) of the ovary, fallopian tube, and peritoneum. The aim of this study was to determine the proportion of women who attended genetics counseling for consideration of BRCA1/2 gene analysis. We also sought to examine if regional differences in consultation rate exist across administrative health regions in the province of Ontario. METHODS: We identified all women with a pathological diagnosis of HGSC in the province of Ontario between 1997 until 2011...
January 9, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28060918/the-impact-of-the-duration-of-adjuvant-chemotherapy-on-survival-in-patients-with-epithelial-ovarian-cancer-a-retrospective-study
#7
Veronika Seebacher, Alexander Reinthaller, Heinz Koelbl, Nicole Concin, Regina Nehoda, Stephan Polterauer
OBJECTIVE: The aim of the present study was to investigate the prognostic role of the duration of adjuvant chemotherapy in patients with epithelial ovarian, fallopian tube and primary peritoneal cancer (EOC). MATERIALS AND METHODS: Within the present study we retrospectively evaluated the data of 165 consecutive patients with EOC treated with primary surgery followed by six completed cycles of platinum-taxan based intravenous adjuvant chemotherapy. Medians of total duration of chemotherapy were compared with clinical-pathological parameters...
2017: PloS One
https://www.readbyqxmd.com/read/28057128/-expression-and-function-of-long-intergenic-non-protein-coding-rna-regulator-of-reprogramming-in-high-grade-ovarian-serous-cancer
#8
H H Jiang, Y H Lou, X Y Wang, Y Han, Z M Cui
Objective: To investigate the expression of long intergenic non-protein coding RNA-regulator of reprogramming (Linc-ROR) in high-grade ovarian serous cancer, and explore the relationship between Linc-ROR expression and biological function of high-grade ovarian serous cancer. Methods: A total of 34 high-grade ovarian serous cancer tissue samples and 19 normal fallopian tube tissue samples were collected between June 2014 and February 2016. Real-time reverse transcription (RT)-PCR was used to detect the Linc-ROR mRNA expression in different samples...
December 25, 2016: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/28054715/tubal-origin-of-ovarian-cancer-the-double-edged-sword-of-haemoglobin
#9
Shiou-Fu Lin, Emily Gerry, Ie-Ming Shih
Ovarian high-grade serous carcinoma (HGSC) is the most malignant neoplasm of the gynaecologic tract. While the origins of many human malignant neoplasms are clear, the origin of HGSC remains poorly understood. This lack of knowledge limits our understanding of its pathogenesis and compromises efforts devoted to develop better early detection tools and effective preventative intervention. The tubal origin of HGSC has been put forward since the initial report of dysplastic lesions (now known as serous tubal intraepithelial carcinomas, or STICs) that morphologically resemble HGSC in the fallopian tube...
January 5, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28029313/safety-and-activity-of-mirvetuximab-soravtansine-imgn853-a-folate-receptor-alpha-targeting-antibody-drug-conjugate-in-platinum-resistant-ovarian-fallopian-tube-or-primary-peritoneal-cancer-a-phase-i-expansion-study
#10
Kathleen N Moore, Lainie P Martin, David M O'Malley, Ursula A Matulonis, Jason A Konner, Raymond P Perez, Todd M Bauer, Rodrigo Ruiz-Soto, Michael J Birrer
Purpose This phase I expansion cohort study evaluated the safety and clinical activity of mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate consisting of a humanized anti-folate receptor alpha (FRα) monoclonal antibody linked to the tubulin-disrupting maytansinoid DM4, in a population of patients with FRα-positive and platinum-resistant ovarian cancer. Patients and Methods Patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer received IMGN853 at 6...
December 28, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28027849/chemotherapy-for-epithelial-ovarian-fallopian-tube-and-primary-peritoneal-cancer
#11
REVIEW
Kate Webber, Michael Friedlander
Chemotherapy plays a key role in the management of women with epithelial ovarian, fallopian tube and primary peritoneal cancer (EOC). Platinum- and taxane-based regimens are the standard of care for adjuvant treatment in early-stage EOC and first-line therapy for advanced stage disease. Efforts to define the optimal scheduling, timing and route of administration are ongoing. The majority of women with EOC will develop recurrent disease, and treatment options for these women are depend on the time that has elapsed from first-line therapy...
November 23, 2016: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/28017973/incidental-prophylactic-salpingectomy-at-benign-gynecologic-surgery-and-cesarean-section-a-survey-of-practice-in-austria
#12
F L Potz, G Tomasch, S Polterauer, R Laky, C Marth, K Tamussino
Introduction: Most serous ovarian cancers are now thought to originate in the fallopian tubes. This has raised the issue of performing incidental salpingectomy (also called elective, opportunistic, prophylactic or risk-reducing salpingectomy) at the time of benign gynecologic surgery or cesarean section. We conducted an online survey to ascertain the policies regarding incidental salpingectomy in Austria in late 2014. Material and Methods: All 75 departments of obstetrics and gynecology in public hospitals in Austria were surveyed for their policies regarding incidental salpingectomy at benign gynecologic surgery or cesarean section...
December 2016: Geburtshilfe und Frauenheilkunde
https://www.readbyqxmd.com/read/28007588/the-role-of-fallopian-tubes-in-the-development-of-ovarian-cancer
#13
REVIEW
Camila Corzo, Maria D Iniesta, Maria Guadalupe Patrono, Karen H Lu, Pedro T Ramirez
Ovarian cancer is the leading cause of death from gynecologic malignancy and the fifth cause of cancer death in women in the United States. The most common and lethal histologic subtype of epithelial ovarian cancer is high-grade serous carcinoma (HGSC), and it generally presents at advanced stage and it may be associated with BRCA1 and BRCA2 mutations. Historically, HGSC was thought to originate from the ovarian epithelial cells. However, more recently, there is growing evidence to support that the vast majority of ovarian cancers originate in the fallopian tube epithelium in both high-risk women and in the general population...
December 19, 2016: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/28002208/ovarian-cancer-follow-up-a-preliminary-comparison-of-2-approaches
#14
Anne Lanceley, Carlo Berzuini, Matthew Burnell, Sue Gessler, Stephen Morris, Andy Ryan, Jonathan A Ledermann, Ian Jacobs
OBJECTIVE: The aim of the study was to perform a preliminary comparison of quality of life (QoL) and patient satisfaction in individualized nurse-led follow-up versus conventional medical follow-up in ovarian cancer. METHODS: One hundred twelve women who received a diagnosis of ovarian, fallopian tube, or peritoneal cancer, completed primary treatment by surgery alone or with chemotherapy, irrespective of outcome with regard to remission, and expected survival of more than 3 months...
January 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27998856/-expression-of-atpase-inhibitory-factor-1-in-normal-and-pathological-tissues-of-female-reproductive-system
#15
Jun Zhao, Xiao Liu, Ya-Li Li
OBJECTIVE: To determine ATPase inhibitory factor 1 (IF1) expression in normal and pathological tissue of female reproductive system to better understand the physiological role of IF1 in malignancies of the female reproductive system. METHODS: Surgical specimens of normal tissues and primary malignant tumors were obtained during the past 2 years, including 38 normal endometrium tissues, 33 endometriosis tissues, 30 endometrial adenocarcinoma tissues, 24 uterine myoideum tissues, 30 uterine fibroid tissues, 18 normal cervical tissues, 30 cervical squamous carcinoma tissues, 11 fallopian tube tissues, 19 fallopian tube adenocarcinoma tissues, 15 ovarian tissues, 21 ovarian endometrial adenocarinoma tissues, 30 decidua tissues, and 30 villus tissues...
December 20, 2016: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/27998236/randomized-phase-ii-trial-of-seribantumab-in-combination-with-paclitaxel-in-patients-with-advanced-platinum-resistant-or-refractory-ovarian-cancer
#16
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, Andrés M Poveda, David Cibula, Hal Hirte, Felix Hilpert, Francesco Raspagliesi, Laurence Gladieff, Philipp Harter, Salvatore Siena, Josep Maria Del Campo, Isabelle Tabah-Fisch, Joseph Pearlberg, Victor Moyo, Kaveh Riahi, Rachel Nering, William Kubasek, Bambang Adiwijaya, Akos Czibere, R Wendel Naumann, Robert L Coleman, Ignace Vergote, Gavin MacBeath, Eric Pujade-Lauraine
Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) -mediated ErbB3 signaling and inducing ErbB3 receptor downregulation. This open-label randomized phase II study evaluated progression-free survival (PFS) with seribantumab in combination with once-per-week paclitaxel compared with paclitaxel alone in patients with platinum-resistant or -refractory ovarian cancer. A key secondary objective was to determine if any of five prespecified biomarkers predicted benefit from seribantumab...
December 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27995370/the-impact-of-ultra-radical-surgery-in-the-management-of-patients-with-stage-iiic-and-iv-epithelial-ovarian-fallopian-tube-and-peritoneal-cancer
#17
Hilary L Turnbull, Nikolaos Akrivos, Simon Wemyss-Holden, Balachandra Maiya, Timothy J Duncan, Joaquin J Nieto, Nikolaos Burbos
OBJECTIVE: The aim of this study is to estimate the percentage of patients with metastatic ovarian, fallopian tube, and primary peritoneal cancer requiring ultra-radical surgery to achieve cytoreduction to less than 1 cm (optimal) or no macroscopic residual disease (complete). METHODS: Perioperative data were collected prospectively on consecutive patients undergoing elective cytoreductive surgery for metastatic epithelial ovarian, fallopian tube, or primary peritoneal cancer at the Norfolk and Norwich University Hospital, a tertiary referral cancer centre in the United Kingdom from November 2012 to June 2016...
December 19, 2016: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/27994671/reduction-of-ca125-levels-during-neoadjuvant-chemotherapy-can-predict-cytoreduction-to-no-visible-residual-disease-in-patients-with-advanced-epithelial-ovarian-cancer-primary-carcinoma-of-fallopian-tube-and-peritoneal-carcinoma
#18
Jing Zeng, Jie Yin, Xiao Song, Ying Jin, Yan Li, Lingya Pan
Background and aims. To determine whether reduction of CA125 levels is a predictive factor for cytoreduction to no visible residual disease (NVRD) and chemotherapeutic sensitivity in advanced epithelial ovarian carcinoma (EOC), primary carcinoma of fallopian tube and peritoneal carcinoma patients who received neoadjuvant chemotherapy followed by interval debulking surgery (NAC-IDS). Methods. This was a single-team-based study of advanced EOC, primary carcinoma of fallopian tube and peritoneal carcinoma patients diagnosed between 1996 and 2015 at Peking Union Medical College Hospital...
2016: Journal of Cancer
https://www.readbyqxmd.com/read/27991925/pax2-function-regulation-and-targeting-in-fallopian-tube-derived-high-grade-serous-ovarian-cancer
#19
D A Modi, R D Tagare, S Karthikeyan, A Russo, M Dean, D A Davis, D D Lantvit, J E Burdette
The fallopian tube epithelium (FTE) is one of the progenitor populations for high-grade serous ovarian cancer (HGSC). Loss of PAX2 is the earliest known molecular aberration in the FTE occurring in serous carcinogenesis followed by a mutation in p53. Pathological studies report consistent loss of PAX2 in benign lesions as well as serous tumors. In the current study, the combined loss of PAX2 and expression of the R273H p53 mutant protein in murine oviductal epithelial (MOE) cells enhanced proliferation and growth in soft agar in vitro but was insufficient to drive tumorigenesis in vivo...
December 19, 2016: Oncogene
https://www.readbyqxmd.com/read/27981938/laparoscopic-restaging-surgery-for-ovarian-or-fallopian-tube-cancer
#20
Merve Bicer, Mert Gol, Cigdem Karas, Zekeriya Guner, Suleyman Akarsu
No abstract text is available yet for this article.
November 2016: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
keyword
keyword
43221
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"